

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

June 24, 2004

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 23, 2004**

**IntraBiotics Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>0-29993</b>	<b>94-3200380</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

**2483 East Bayshore Road, Suite 100  
Palo Alto, California 94303**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

**Not Applicable**

---

(Former name or former address, if changed since last report.)

---

---

---

**TABLE OF CONTENTS**

Item 5. Other Events.

Item 7. Financial Statements and Exhibits.

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

---

**Table of Contents**

Item 5. Other Events.

On June 23, 2004, IntraBiotics Pharmaceuticals, Inc. announced that it had stopped its iseganan trial in ventilator-associated pneumonia for safety reasons. A copy of the related press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

Item 7. Financial Statements and Exhibits.

(c) Exhibits. The following documents are filed as exhibits to this report:

99.1 Press Release, dated June 23, 2004, entitled IntraBiotics Stopped Isegaran Trial in Ventilator-Associated Pneumonia for Safety Reasons.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**INTRABIOTICS  
PHARMACEUTICALS, INC.**

Date: June 24, 2004

/s/ David Tucker  
David Tucker  
Principal Financial Officer

---

**Table of Contents**

**INDEX TO EXHIBITS**

- 99.1 Press Release, dated June 23, 2004, entitled IntraBiotics Stopped Iseganan Trial in Ventilator-Associated Pneumonia for Safety Reasons.